Drug intelligence / Profile preview

nano selenium capsules

Development stage: Preclinical
Lead developer: Zhuhai People's Hospital
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

Nano selenium capsules are an oral formulation of selenium nanoparticles (SeNPs) being evaluated as an adjunctive therapy for acute ischemic stroke. Developed by Zhuhai People's Hospital, the treatment is intended to be used in combination with vascular recanalization therapy to enhance functional recovery. The mechanism of action centers on the reduction of oxidative stress and the modulation of selenoenzyme expression, which helps protect neural tissue from ischemia-reperfusion injury. Selenium nanoparticles are utilized for their improved bioavailability and reduced toxicity compared to traditional inorganic selenium salts.

Other names: nano-seleniumnanoseleniumSeNPsselenium nanoparticles

Targets

GPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on nano selenium capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nano selenium capsules.